InMode Ltd. (NASDAQ:INMD) Given Average Recommendation of “Hold” by Brokerages

InMode Ltd. (NASDAQ:INMD) has received a consensus recommendation of “Hold” from the five research firms that are presently covering the company, MarketBeat.com reports. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the company. The average 12 month target price among brokers that have covered the stock in the last year is $21.25.

INMD has been the subject of several research analyst reports. Barclays upped their price objective on shares of InMode from $26.00 to $29.00 and gave the company an “overweight” rating in a research note on Wednesday, February 5th. Needham & Company LLC reissued a “hold” rating on shares of InMode in a report on Monday. Jefferies Financial Group cut their target price on shares of InMode from $16.00 to $15.00 and set a “hold” rating on the stock in a report on Monday, April 14th. Finally, Robert W. Baird cut shares of InMode from an “outperform” rating to a “neutral” rating and decreased their price target for the stock from $22.00 to $16.00 in a research note on Monday.

Hedge Funds Weigh In On InMode

Several institutional investors have recently bought and sold shares of INMD. Orion Capital Management LLC acquired a new position in shares of InMode during the fourth quarter worth about $65,000. SBI Securities Co. Ltd. acquired a new position in InMode during the 4th quarter worth approximately $87,000. Farther Finance Advisors LLC increased its position in InMode by 26.2% during the 4th quarter. Farther Finance Advisors LLC now owns 5,555 shares of the healthcare company’s stock worth $93,000 after purchasing an additional 1,154 shares during the period. Covestor Ltd lifted its holdings in shares of InMode by 13.9% in the 4th quarter. Covestor Ltd now owns 5,936 shares of the healthcare company’s stock valued at $99,000 after buying an additional 723 shares during the period. Finally, Lazard Asset Management LLC lifted its holdings in shares of InMode by 6,128.7% in the 4th quarter. Lazard Asset Management LLC now owns 6,291 shares of the healthcare company’s stock valued at $105,000 after buying an additional 6,190 shares during the period. 68.04% of the stock is owned by institutional investors and hedge funds.

InMode Trading Down 13.8 %

Shares of INMD stock traded down $2.23 on Monday, reaching $13.99. 3,255,115 shares of the stock were exchanged, compared to its average volume of 1,183,851. InMode has a twelve month low of $13.68 and a twelve month high of $19.85. The company has a market capitalization of $972.85 million, a price-to-earnings ratio of 5.95 and a beta of 1.96. The business’s 50 day moving average price is $17.36 and its 200 day moving average price is $17.65.

InMode Company Profile

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.